The Happy Medium. Principles of Appropriate Prescribing Across the Aging Spectrum Milta Oyola Little, DO, CMD

Size: px
Start display at page:

Download "The Happy Medium. Principles of Appropriate Prescribing Across the Aging Spectrum Milta Oyola Little, DO, CMD"

Transcription

1 The Happy Medium Principles of Appropriate Prescribing Across the Aging Spectrum Milta Oyola Little, DO, CMD

2 Disclosures Dr. Little has no relevant financial relationships to report. Dr. Little will not be discussing any unapproved or off-label uses of medications or products.

3 Objectives At the end of the session, participants will 1. Define polypharmacy and describe the impact of inappropriate prescribing on the frail elderly 2. Describe strategies to reduce or prevent inappropriate prescribing, including the use of drugspecific tools 3 Identify common chronic disease conditions associated with inappropriate prescribing and medication errors in older adults.

4 What is Polypharmacy? More than 24 distinct definitions Extraordinary Prescribing A patient is taking more medications than necessary Medications are prescribed for an inappropriate indication Inappropriate Prescribing Bushardt RL, et al. Clin Interv Aging 2008;3(2): Gillette C, et al. Res Social and Admin Pharm 2015;11:468-71

5 What is Polypharmacy? A. 85 y/o male with COPD, diabetes and CHF on 14 routine and 6 PRN medications B. 72 y/o female with fibromyalgia, hypertension, depression and osteoarthritis on four medications who gets her prescriptions written and refilled by her PCP, rheumatologist, psychiatrist and orthopedist. C. 90 y/o male with dementia on no medications prescribed routine omeprazole 80 mg twice a day and ranitidine 150 mg twice a day after an episode of vomiting (both of these medicine reduce acid in the stomach) Too many meds Too many prescribers No indication

6 Prevalence of Inappropriate Prescribing Charlesworth CJ, et al. Polypharmacy Among Adults Aged 65 Years and Older in the United States: J Gerontolog A Biol Sci Med Sci, 2015,

7 Inappropriate Prescribing Bootman, et al. Arch Int Med 1997;157: Field, et al. JAGS 2004; 52: Planton and Edlund. J Gerontol Nursing 2010; 36: 8-12 Adverse Drug Reactions 5% to 28% of acute geriatric hospital admissions 13% on 2 medications develop ADR 82% on 6 or more medications develop ADR For every $1 spent on medications in nursing homes, $1.33 was spent on treating ADR

8 Inappropriate Prescribing and Aging Older patients are two to three times more likely to experience adverse effects of drugs than younger patients > 6 meds associated with frailty > 4 meds associated with falls Zia A, et al. Postgrad Med, 2015; 127(3): Moulis F, et al. JAMDA 16 (2015) 258e261 Chiu MH et al. Geriatr Gerontol Int 2015; 15:

9 Polypharmacy Mortality Jyrkkä J, et al. Drugs Aging. 2009;26(12): Beer C, et al. Br J Clin Pharmacol Apr;71(4):592-9 Gomez C, et al. Gerontology 2015;61:

10 GENERAL STRATEGIES TO DEPRESCRIBING

11 Deprescribing The act of systematically identifying and tapering, reducing or stopping medications that are not indicated (either because of previous misdiagnosis or evidence of no benefit or harm for a true diagnosis), or are causing, or have considerable potential to cause, adverse effects. I. A. Scott1,2 and D. G. Le Couteur3,4 Internal Medicine Journal 45 (2015)

12 Good Outcomes of Deprescribing Systematic deprescribing associated with Fall reduction Improved cognitive and psychomotor function Reduced mortality Reduction in healthcare utilization (ED visits and readmissions) WITHOUT increased risk of adverse outcome Potter K, et al. PLoS ONE. 2016;11(3):e Scott IA, et al. JAMA Intern Med. 2015;175(5): Zia A, et al. Postgrad Med, 2015; 127(3): van der Cammen TJ, et al. Age Ageing 2014;43:20 5. Salonoja M, et al. Arch Gerontol Geriatr 2012;54: van der Velde N, et al. Br J Clin Pharmacol 2007;63: Roberts, et al. Br J Clin Pharmacol 2001; 51:

13 When to Deprescribe? Limited life expectancy, functional dependency, severity of cognitive impairment High-risk medication classes Chróinín DN, et al. Age and Ageing 2015; 44: Benzodiazepines, atypical antipsychotics, statins, TCAs, PPI Farrell B, PLoS ONE (4): e New symptom or syndrome suggestive of ADR Preventive drugs when benefit maximized Scott IA, et al. JAMA Intern Med. 2015;175(5):

14 When to Deprescribe? Limited life expectancy Many patients are given inappropriate preventative medications in advanced illness Limited but preliminary evidence of increased life expectancy and quality of life with deprescribing Garfinkel D, et al. Isr Med Assoc J 2007;9: Kutner JS, et al. JAMA Intern Med 2015;175: Todd A, et al. BMJ Supportive & Palliative Care 2016;0:1 9.

15 Barriers to Deprescribing High levels of clinical complexity Limited consultation time Fragmented care among multiple prescribers Incomplete information Ambiguous or changing care goals Uncertainty about the benefits and harms of continuing or discontinuing specific drugs Community and professional attitudes toward more rather than less use of drugs Fear of adverse drug withdrawal effects Pressure to prescribe evoked by recommendations in disease-specific clinical guidelines Scott IA, et al. JAMA Intern Med. 2015;175(5):

16 Using Guidelines Most guidelines are based on evidence that excludes frail or institutionalized older adults Most guidelines are based on evidence that excludes people with multimorbidity Many recommendations in guidelines are based on expert opinion with moderate to weak evidence

17 General Principles to Reducing The Happy Medium Polypharmacy Life expectancy Quality of Life Drug-drug and drug-disease interactions Up to 82% of patients on 6 or more medicines experience a drug interaction Amery A, et al. Lancet 1985; 1:

18 Scott IA, et al. JAMA Intern Med. 2015;175(5):

19 Scott IA, et al. JAMA Intern Med. 2015;175(5):

20 Case: Frail Older Adult 97 year old man. A medication review was requested due to multiple falls. Orthostatic blood pressure monitoring is incomplete. His systolic BP ranges from under 100 to 140. He is receiving 12 routine medications. His daughter doesn t want any medication stopped. SEE CASE INCLUDED IN FOLDER

21 Role of the Interprofessional Team Identify a diagnosis for every medication Be mindful of the prescribing cascade Partner with clinical pharmacists Consider computerized decision aids Use a specific tool to monitor and reconcile medications regularly Scott IA. Am J Med 2012; 125(6): Planton J. J Gerontol Nurs 2012; 36(1): 8-12 Meyer, T.J. J Gen Int Med 1991; 6, Kripalani S. Journal of Hospital Medicine 2007;2: Haque, R. Ann Long-Term Care 2009;17(6): Meulendijk MC, et al. Drugs Aging (2015) 32:

22 Drug-Specific Tools BEERS STOPP/START ARMOR Medication Discrepancy Tool Medication Appropriateness Index

23 BEERS Criteria 2015 Update American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc Nov;63(11):

24 American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc Nov;63(11):

25 American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc Nov;63(11):

26 American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc Nov;63(11):

27 Steinman MA, et al. J Am Geriatr Soc Nov;63(11):e1-e7

28 Screening Tool of Older Persons Prescriptions STOPP The following prescriptions are potentially inappropriate in persons aged > 65 years of age By system: CV, CNS/psychotropic, GI, Resp, MSK, GU, Endo, falls, analgesic, duplicate drug classes Screening Tool to Alert to Right Treatment START These medications should be considered for people > 65 years of age with the following conditions, where no contra-indications to prescription exists By system: CV, Resp, CNS, GI, MSK, endo O Mahony D, et al. European Geriatr Med 2010; 1:45-51

29 ARMOR: Nursing Home Med Rec 1. # Meds 2. Specific drug classes

30

31 Medication Appropriateness Index Hanlon JT, et al. J Clin Epidemiol 1992; 45(10):

32 Pill Pruner for Inpatient Deprescribing Chieng JHC, et al. Australasian Journal on Ageing, Vol 34 No 1 March 2015, 58 61

33 Pill Pruner for Inpatient Deprescribing Chieng JHC, et al. Australasian Journal on Ageing, Vol 34 No 1 March 2015, 58 61

34 Applying the Principle of the Happy Medium TARGETING SPECIFIC DRUG CLASSES

35 Clinical Vignette: Mr. Casino 76 y/o male admitted to SNF s/p parieto-occipital CVA Aortic aneurism HTN Pre-DM CAD PVD Renal artery stenosis CVA Dementia GERD Weight loss A-fib/SSS s/p pacer

36 Mr. Casino Esomeprazole 40 mg daily Dicyclomine 10 mg BID Sucralfate 1 GM QID Famotidine 20 mg BID Warfarin 5 mg daily Aspirin 81 mg daily Levetiracetam 500 mg BID Atorvastatin 20 mg daily Nitrofurantoin 100 mg BID for 7 days Doxazosin 1 mg daily Lisinopril 20 mg daily Metoprolol tartrate 25 mg BID Clonidine 0.1 mg BID PRN: Zopidem 5 mg at HS Hydrocodone/APAP 5/324 mg q 8hrs VS: 125/ #

37 Port S, et al. Systolic blood pressure and mortality. Lancet 2000;355:177.

38 Denardo SJ, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med 2010;123:725

39 2014 Hypertension Guidelines (JNC-8) James, PA, et al. JAMA 2014; 311(5):

40 First line Thiazides Hyponatremia, hypokalemia, hypercalcemia, incontinence ACEi/ARB Diabetes, heart failure, post-mi, CKD, sarcopenina. Hyperkalemia, AKI, angioedema, cough (ACEi) CCB Constipation, edema, and heart failure. Others Beta-Blockers: heart failure, postmyocardial infarction, atrial arrhythmia poorly tolerated in older people Alpha-blockers ONLY if benign prostatic hypertrophy. James, PA, et al. JAMA 2014; 311(5): Little MO. Med Clin N Am 2011; 95 (3):

41 What About the SPRINT Trial? N Engl J Med 2015;373: Does it apply to my patient? Excluded patients with DM, previous CVA, ESRD, prior CV procedure, symptomatic CHF in past 6 months, dementia, NH residents 5/6 patients currently treated for HTN don t meet study criteria 2. How were the blood pressures measured? Mean of 3 BP readings at an office visit while the patient was seated and after 5 minutes of quiet rest; Using an automated measurement system Some variation between clinical sites 3. How do the statistical results translate clinically? Per 1000 patients: 16 benefit, 22 harmed, 962 neither The likelihood of absolute benefit is 1.6% A serious increase in ADEs in the aggressively Rx d group (2.5% to 4.7%) Ortiz, E. et al. Ann Intern Med.2016;164(10): Messerli and Bangalore. Am J Medicine. 2016;129(8):

42 HTN Trials Relevant to Frail Elderly PARTAGE nursing home study SBP < 130 on > 2 antihypertensives had twofold greater risk of 2-year mortality Low BP in those NOT on anti-htn was NOT associated with higher mortality -blockers post acute MI in NH Decreased 90-day mortality Increased functional decline Benetos A, et al. JAMA Inter Med 2015;175: Steinman MA, et al. JAMA Intern Med 2017;177:

43 Mr. Casino Esomeprazole 40 mg daily Dicyclomine 10 mg BID Sucralfate 1 GM QID Famotidine 20 mg BID Warfarin 5 mg daily Aspirin 81 mg daily Levetiracetam 500 mg BID Atorvastatin 20 mg daily Nitrofurantoin 100 mg BID for 7 days Doxazosin 1 mg daily Lisinopril 20 mg daily Metoprolol tartrate 25 mg BID Clonidine 0.1 mg BID PRN: Zopidem 5 mg at HS Hydrocodone/APAP 5/324 mg q 8hrs VS: 125/ #

44 Should I start, continue or stop the cholesterollowering medications?

45 Cholesterol Guidelines Based on RCTs and Meta-analyses: reduction of atherosclerotic cardiovascular disease (ASCVD) NO RCT evidence to support titrating drugs to achieve target LDL C or non-hdl-c levels YES RCT evidence that additional drugs (e.g. niacin) to lower non-hdl C did not further reduce ASCVD outcomes Stone NJ, et al ACC/AHA Blood Cholesterol Guideline

46 Cholesterol Guidelines 4 Statin Benefit Groups: 1. Individuals with clinical ASCVD 2. Individuals with primary elevations of LDL C 190 mg/dl 3. Individuals 40 to 75 years of age with diabetes and LDL C 70 to189 mg/dl without clinical ASCVD 4. Individuals without clinical ASCVD or diabetes who are 40 to 75 years of age with LDL C 70 to 189 mg/dl and have an estimated 10-year ASCVD risk of 7.5% or higher. Stone NJ, et al ACC/AHA Blood Cholesterol Guideline

47 Cholesterol Guidelines: Application to Elderly? Few > 75 included in trials Continue for secondary prevention if tolerating Probably no benefit for primary prevention Do not need to routinely measure CK Stone NJ, et al ACC/AHA Blood Cholesterol Guideline

48 Statins and Limited Life Expectancy Stopping statins in patients with1 year or less life expectancy No change in mortality Improved QOL Abernethy AP, et al "Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness" ASCO 2014; Abstract LBA9514. Substantial cost savings

49 PROTON PUMP INHIBITORS

50 Chronic PPI Use - Complications Malabsorption of key minerals / vitamins Calcium Magnesium B12 and Iron anemia Osteoporosis and Fractures Pneumonia C. diff Linsky A, et al Arch Intern Med 2010; 170: CKD Lazarus, B, et al. JAMA Intern Med 2016 MI Shah NH, et al. PLoS ONE 2015;10(6): e Dementia Gomm W, et al. JAMA Neurol 2016 Mortality Xie Y, et al. BMJ Open 2017;7:e Gray SL, et al. Arch Intern Med 2010; 170: O Neill, L., et al. US Pharmacist. 2013;38(12)38-42 Katz M Arch Intern Med 2010; 170:

51 Kurlander J et al, "The right idea in the wrong patient: a national survey of internists' attitudes towards stopping PPIs," DDW 2017; abstract Sa1016.

52 Case: Frail Older Adult 97 year old man. A medication review was requested due to multiple falls. Orthostatic blood pressure monitoring is incomplete. His systolic BP ranges from under 100 to 140. He is receiving 12 routine medications. His daughter doesn t want any medication stopped. SEE CASE INCLUDED IN FOLDER

53 The Difficult Case, i.e. when he wants them all Mr. S.M. 87 y/o male with HTN, moderate Alzheimer s, OA, anemia, HLD, GERD seen in geriatric consult clinic Meds: Aspirin 325 mg daily Lisinopril 20 mg daily VS: 110/ Atorvastatin 20 mg daily Multivitamin daily LDL 72 Vitamin B complex daily HDL 33 Omeprazole 20 mg BID Hgb 10.3 Donepezil 10 mg BID Amlodipine 10 mg daily Ibuprofen 200 mg TID Fish oil 1000 mg BID Alprazolam 0.5 mg BID PRN Has been on these for years and is unwilling to stop any of them.

54 The Difficult Case, i.e. when he wants Think beyond drugs them all Practice more strategic prescribing Maintain heightened vigilance regarding adverse effects Exercise caution and skepticism regarding new drugs Work with patients for a shared agenda Consider long-term, broader impacts Schiff GD, et al. Arch Int Med 2011; 171:

55 SAIL and TIDE SAIL: Keep meds as Simple as possible, remember Adverse effects, identify the Indication for each medication, List each drug and dose TIDE: Schedule Time during each visit to discuss medications, have awareness of Individual response to medications, avoid potential Drug/drug/disease interactions, Educate the patient

56 Questions? YOU can make a difference!

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director Deconstructing Polypharmacy Alan B. Douglass, M.D. Director Recognize this patient? Mrs. Brown- 82 years young Active Medical Problems Hypertension Hyperlipidemia Type 2 Diabetes Peripheral edema Osteoarthritis

More information

Polypharmacy & De-prescribing In Older Adults

Polypharmacy & De-prescribing In Older Adults Polypharmacy & De-prescribing In Older Adults Maryland Association of Osteopathic Physicians Annual Meeting September 15, 2018 Elizabeth Phung, DO Lead Clinical Associate Physician Beacham Center for Geriatric

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Transitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018

Transitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018 Transitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018 Objectives Identify when to complete medication reconciliation Understand the importance

More information

Deprescribing Unnecessary Medications: A Four-Part Process

Deprescribing Unnecessary Medications: A Four-Part Process Deprescribing Unnecessary Medications: A Four-Part Process Scott Endsley, MD Fam Pract Manag. 2018;25(3):28-32. Abstract and Introduction Introduction www.medscape.com Ms. Horatio is a 76-year-old patient

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

DEPRESCRIBING IN THE ELDERLY

DEPRESCRIBING IN THE ELDERLY DEPRESCRIBING IN THE ELDERLY G E R I A T R I C S R E F R E S H E R D A Y W E D N E S D A Y, A P R I L 5 TH, 2 0 1 7 V É R O N I Q U E F R E N C H M E R K L E Y, M D, C C F P ( C O E ) B R U Y È R E C O

More information

Polypharmacy and Polymorbid Patients: Practical Tips and Tricks

Polypharmacy and Polymorbid Patients: Practical Tips and Tricks Polypharmacy and Polymorbid Patients: Practical Tips and Tricks November 2, 2013 Faculty/Presenter Disclosure Faculty: Chris Fan-Lun, BScPhm, ACPR, CGP Pharmacist - Geriatric Medicine Clinical Practice

More information

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension

More information

AGS Annual Meeting May Sponsored by the Polypharmacy Special Interest Group and the Pharmacists Section

AGS Annual Meeting May Sponsored by the Polypharmacy Special Interest Group and the Pharmacists Section AGS Annual Meeting May 2010 Sponsored by the Polypharmacy Special Interest Group and the Pharmacists Section No financial conflicts of interest Sponsored by the Polypharmacy Special Interest Group Thanks

More information

Geriatric Pharmacology

Geriatric Pharmacology Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological

More information

Polypharmacy, Medication Nihilism, and the art of de-prescribing

Polypharmacy, Medication Nihilism, and the art of de-prescribing Polypharmacy, Medication Nihilism, and the art of de-prescribing Temple Family Practice Review Course Leon S. Kraybill, MD, CMD Geriatrics, Lancaster General Hospital Physicians Division Chief, LGH Division

More information

STOPP and START criteria October 2011

STOPP and START criteria October 2011 # START and STOPP are newer criteria to identify potentially inappropriate medications in elderly, including drug drug and drug disease interactions, drugs which increase risk of falls and drugs which

More information

MEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging

MEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging MEDICATION APPROPRIATENESS FOR THE AGING POPULATION Building Partnerships for Successful Aging Learning objectives Appreciate complexities involved in making appropriate clinical decisions in older adults

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

Polypharmacy and Elders. Leslie Baker, Pharm. D., RPh, CGP Sanford Center for Aging

Polypharmacy and Elders. Leslie Baker, Pharm. D., RPh, CGP Sanford Center for Aging Polypharmacy and Elders Leslie Baker, Pharm. D., RPh, CGP Sanford Center for Aging Prescription Medication Use In Elders 1 13% of the US population is age 65+ Age 65 years 13% Age 65+ account for 34% of

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1 Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook

More information

There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients

There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients Marilyn N. Bulloch, PharmD, BCPS Assistant Clinical Professor

More information

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.

We are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients. Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded

More information

Appropriate prescribing and deprescribing for older people getting it right. Alan Davis Northland District Health Board

Appropriate prescribing and deprescribing for older people getting it right. Alan Davis Northland District Health Board Appropriate prescribing and deprescribing for older people getting it right Alan Davis Northland District Health Board Unused returns Potentially inappropriate medication use in the elderly 15% of older

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Optimising Safe & Appropriate Medicines Use and Deprescribing. Katie Smith, Director, East Anglia Medicines Information Service February 2014

Optimising Safe & Appropriate Medicines Use and Deprescribing. Katie Smith, Director, East Anglia Medicines Information Service February 2014 Optimising Safe & Appropriate Medicines Use and Deprescribing Katie Smith, Director, East Anglia Medicines Information Service February 2014 Background Objectives How & why the OSAMU document was developed

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

Polypharmacy and Deprescribing for Older People

Polypharmacy and Deprescribing for Older People Polypharmacy and Deprescribing for Older People Sarah Hilmer Head of Department, Clinical Pharmacology and Senior Staff Specialist Aged Care, RNSH Conjoint Professor of Geriatric Pharmacology, Sydney University

More information

DEPRESCRIBING. Phil St John CSIM Workshop

DEPRESCRIBING. Phil St John CSIM Workshop DEPRESCRIBING Phil St John CSIM Workshop Conflict of Interest Disclosure Consultant for: none Speaker for: none Received grant/research support from: CIHR, MHRC, Riverview Foundation Received honoraria

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Screening tools for elderly patients in primary care

Screening tools for elderly patients in primary care Screening tools for elderly patients in primary care Cristín Ryan 1 Prof. Julia Kennedy 1 Dr. Denis O Mahony 2 Dr. Stephen Byrne 1 Co-Investigator: Dr. Paul Gallagher 2 1 Pharmaceutical Care Research Group,

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

1/21/2016 UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE OBJECTIVES AGING GOALS BEERS CRITERIA

1/21/2016 UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE OBJECTIVES AGING GOALS BEERS CRITERIA UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE I have no financial conflict of interest to disclose. Lacey Charbonneau, Pharm.D. PGY-1 Community Practice Resident Baptist Medical

More information

Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions

Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions Health Outcome Prioritization as a Tool for Decision Making Among Older Persons With Multiple Chronic Conditions Mary Tinetti, M.D. Canadian Geriatrics Society May, 2013 CFPC CoI Templates: Slide 1 Faculty/Presenter

More information

Let it go! Rationalising medicines for patients with life limiting illness

Let it go! Rationalising medicines for patients with life limiting illness Let it go! Rationalising medicines for patients with life limiting illness Inga Andrew Senior Clinical Pharmacist Northumbria Healthcare Trust E-mail: inga_andrew@northumbria-healthcare.nhs.uk Welcome

More information

Rationalizing Medications. Tan Jianming Senior Pharmacist KTPH

Rationalizing Medications. Tan Jianming Senior Pharmacist KTPH Rationalizing Medications Tan Jianming Senior Pharmacist KTPH + Older patients are more likely to: 2 Have multiple co-morbid diseases Have age-related physiological changes that result in a reduced tolerance

More information

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for

More information

Deprescribing in CKD patients: Is less more? Speaker: Dr. Judith G. Marin, PharmD

Deprescribing in CKD patients: Is less more? Speaker: Dr. Judith G. Marin, PharmD 2016 Deprescribing in CKD patients: Is less more? Speaker: Dr. Judith G. Marin, PharmD Case Mr. Kid Ney is a 75 y/o patient who has been on dialysis for the last 4 years (PD, then HD). PMHx: HTN, DM,

More information

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives

More information

About ISMP Canada. Analysis Outputs: Safety Bulletins. Less is More: An Introduction to Deprescribing. canada.org

About ISMP Canada. Analysis Outputs: Safety Bulletins. Less is More: An Introduction to Deprescribing.   canada.org Less is More: An Introduction to Deprescribing Lindsay Yoo, BSc, BScPhm, RPh, CDE, CGP, PharmD Medication Safety Analyst, ISMP Canada About ISMP Canada The Institute for Safe Medication Practices Canada

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

A C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R

A C A D E M I C D E TA I L I N G C H O O S I N G W I S E LY C O N F E R E N C E O C T 2 1, PA M M C L E A N - V E Y S E Y B S C P H A R M D R PPI DEPRESCRIBING Canadian Deprescribing Network (CaDeN) goals are to: Reduce harm by raising awareness and cutting risky prescriptions for seniors by 50% by 2020. Promote health by ensuring access to

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Meds and Falls: Keep in Step with your Meds

Meds and Falls: Keep in Step with your Meds Meds and Falls: Keep in Step with your Meds Donna Bartlett PharmD, CGP, RPh Associate Professor-Pharmacy Practice MCPHS University Clinical Pharmacist-MCPHS University- Pharmacy Outreach Program donna.bartlett@mcphs.edu

More information

Objectives. Case Ruby. 1- Warfarin. 1- Warfarin. Warfarin discontinuation 8/13/ DRUGS TO STOP GIVING HOSPICE PATIENTS

Objectives. Case Ruby. 1- Warfarin. 1- Warfarin. Warfarin discontinuation 8/13/ DRUGS TO STOP GIVING HOSPICE PATIENTS Objectives 10 DRUGS TO STOP GIVING HOSPICE PATIENTS Richard E. Allen MD, MPH Hospice Medical Director Family Medicine Residency Director Salt Lake City, Utah 2 Recognize 10 commonly prescribed medications

More information

Hypertension 2015: Recent Evidence that Will Change Your Practice

Hypertension 2015: Recent Evidence that Will Change Your Practice Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

BLCS 1-Clinical Overview. Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative

BLCS 1-Clinical Overview. Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative BLCS 1-Clinical Overview Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative Fraser Health Guide To Person-Centered Medication Decisions Factors to Consider When Systematically

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

Appropriateness of prescribing in older patients

Appropriateness of prescribing in older patients Appropriateness of prescribing in older patients Which tools should be used? Anne Spinewine MPharm, MSc, PhD Université catholique de Louvain, Belgium Louvain Drug Research Institute and CHU Mont-Godinne

More information

Hypertension and Cholesterol in the Elderly

Hypertension and Cholesterol in the Elderly Hypertension and Cholesterol in the Elderly Angela Sanford, MD Assistant Professor of Geriatrics Saint Louis University School of Medicine I have no relevant financial disclosures Cushman WC. The burden

More information

Lipid Panel Management Refresher Course for the Family Physician

Lipid Panel Management Refresher Course for the Family Physician Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College

More information

Modern Management of Hypertension

Modern Management of Hypertension Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence

More information

Murthy Gokula MD,CMD

Murthy Gokula MD,CMD Murthy Gokula MD,CMD MEDICATIONS & LIFE EXPECTANCY DON T ROUTINELY PRESCRIBE LIPID-LOWERING MEDICATIONS IN INDIVIDUALS WITH A LIMITED LIFE EXPECTANCY: AAHPM About Choosing Wisely First conceived by the

More information

Strategies to Decrease Medication Errors in Elderly. Abeer Zeitoun, Pharm. D Certified in Medication Safety, MCPHS

Strategies to Decrease Medication Errors in Elderly. Abeer Zeitoun, Pharm. D Certified in Medication Safety, MCPHS Strategies to Decrease Medication Errors in Elderly Abeer Zeitoun, Pharm. D Certified in Medication Safety, MCPHS Road Map..Outline 1. Introduction A. Definitions B. Geriatrics: High risk population C.

More information

Disclosure. The elderly at risk: reducing medications safely to meet life s changes. Relevant financial relationships.

Disclosure. The elderly at risk: reducing medications safely to meet life s changes. Relevant financial relationships. The elderly at risk: reducing medications safely to meet life s changes Barbara Farrell BScPhm, PharmD, FCSHP European Society of Hospital Pharmacists Conference March 2017 Disclosure Relevant financial

More information

ASPIRIN MISUSE AT HOME ACCORDING TO START AND STOPP IN FRAIL OLDER PERSONS

ASPIRIN MISUSE AT HOME ACCORDING TO START AND STOPP IN FRAIL OLDER PERSONS ASPIRIN MISUSE AT HOME ACCORDING TO START AND STOPP IN FRAIL OLDER PERSONS O. Dalleur 1,4, B. Boland 2,3, A. Spinewine 4-5 1 Pharmacy and 2 Geriatric Medicine, St-Luc university Hospital, 3 Institute of

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE

POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE Jeannie Kim Lee, PharmD, BCPS, CGP Clinical Pharmacy Director College of Pharmacy The University of Arizona Learning Objectives: State the risks of

More information

Disclosures. Use caution in the elderly: review of safe and effective medication use in older patients. Institute of Medicine. Learning Objectives

Disclosures. Use caution in the elderly: review of safe and effective medication use in older patients. Institute of Medicine. Learning Objectives Use caution in the elderly: review of safe and effective medication use in older patients Disclosures I have no disclosures or conflicts of interest related to this presentation John T. Holmes, PharmD,

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

Integrating Goals of Care Discussions into Routine Care

Integrating Goals of Care Discussions into Routine Care Integrating Goals of Care Discussions into Routine Care Kenneth Brummel-Smith, MD Charlotte Edwards Maguire Professor Department of Geriatrics Florida State University College of Medicine Objectives Define

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

Hypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS

Hypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS Hypertension and the Challenge of Adherence Geneva Clark Briggs, Pharm.D., BCPS Outline Brief overview of HTN and pharmacologic therapies Role of pharmacists in collaboration with patients and physicians

More information

Medicines in Older People- Some of the Key Issues

Medicines in Older People- Some of the Key Issues Medicines in Older People- Some of the Key Issues Associate Professor Vasi Naganathan Sydney Medical School Consultant Geriatrician, Centre for Education and Research on Ageing Concord Hospital, Sydney,

More information

< = > less is more. De-diagnosing De-prescribing Non-testing

< = > less is more. De-diagnosing De-prescribing Non-testing < = > less is more De-diagnosing De-prescribing Non-testing Who says? Overdiagnosis Polypharmacy False positives Too much medicine Risk aversion $$$ Sources Prof David Le Couteur, Clin Pharm and Aged Care

More information

Hypertension in the very old. Objectives: Clinical Perspective

Hypertension in the very old. Objectives: Clinical Perspective Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

What in the World is Functional Medicine?

What in the World is Functional Medicine? What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They

More information

Updates in Cardiovascular Recommendations for Diabetic Patients

Updates in Cardiovascular Recommendations for Diabetic Patients Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy

More information

Prescribing appropriately. May 2016

Prescribing appropriately. May 2016 Prescribing appropriately May 2016 Prescribing process Prescribing process Patient problem Core knowledge Decision to prescribe Medicines Choice Modification Habit Formulation Dose Frequency Preferred

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Shared decision making for stepdown and stopping decisions. Michael R. Gionfriddo Pharm.D, Ph.D Geisinger Center for Pharmacy Innovation and Outcomes

Shared decision making for stepdown and stopping decisions. Michael R. Gionfriddo Pharm.D, Ph.D Geisinger Center for Pharmacy Innovation and Outcomes Shared decision making for stepdown and stopping decisions Michael R. Gionfriddo Pharm.D, Ph.D Geisinger Center for Pharmacy Innovation and Outcomes 1 Disclosures I have had travel and lodging paid for

More information

Less is More: Introduction to Deprescribing

Less is More: Introduction to Deprescribing Less is More: Introduction to Deprescribing 7th Annual Pharmaceutical Care Conference Muscat, Oman Feb 23, 2017 Lindsay Yoo, BSc, BScPhm, RPh, CDE, CGP, PharmD Medication Safety Analyst, ISMP Canada About

More information

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016

Evaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016 Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has

More information

2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016

2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016 2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016 I have no conflicts of interest Photos thanks to Google images This year

More information

Katee Kindler, PharmD, BCACP

Katee Kindler, PharmD, BCACP Speaker Introduction Katee Kindler, PharmD, BCACP Current Practice: Clinical Pharmacy Specialist Ambulatory Care, St. Vincent Indianapolis Assistant Professor of Pharmacy Practice, Manchester University,

More information

Anthony J. Caprio, MD, CMD, AGSF 1

Anthony J. Caprio, MD, CMD, AGSF 1 Objectives 1) Discuss the dangers of polypharmacy 2) Review potentially inappropriate medications for older adults Doc, I think I am taking too many medications! 3) Develop strategies for prioritizing

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Interprofessional Outpatient Clinic Polypharmacy Management. Objectives

Interprofessional Outpatient Clinic Polypharmacy Management. Objectives Interprofessional Outpatient Clinic Polypharmacy Management Brett Hoffecker, MD University of Kansas School of Medicine Wichita Family Medicine Residency Program at Via Christi April 10th, 2015 Objectives

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Deprescribing with Confidence Dr Sanjay Suman MD FRCP

Deprescribing with Confidence Dr Sanjay Suman MD FRCP Deprescribing with Confidence Dr Sanjay Suman MD FRCP Clinical Director Elderly Care and Stroke Medway NHS Foundation Trust Kent 45% of all medications prescribed for 65 years 1 1. Wynne et al Maturitas

More information

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests

More information

START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy

START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy Jessica DiLeo, PharmD Kate Murphy, PharmD OBJECTIVES Identify pharmacodynamic and pharmacokinetic parameters that may influence treatment

More information

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy

More information

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News

Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News Hot Off the Press and into Your Practice: The Last Year in Medical News Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Moyer VA, et al. Ann Internal Med. 2014;160(5):330-338.

More information

Medication Assessment and Quality Parameters. Norma J. Owens, PharmD, FCCP Professor of Pharmacy University of Rhode Island

Medication Assessment and Quality Parameters. Norma J. Owens, PharmD, FCCP Professor of Pharmacy University of Rhode Island Medication Assessment and Quality Parameters Norma J. Owens, PharmD, FCCP Professor of Pharmacy University of Rhode Island Financial Disclosure None of the planners, speakers, and/or members of the CME

More information